Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 38Sarcoma 21Lymphoid 12Genitourinary 12Gastrointestinal 12Gynecologic 6Other hematologic neoplasm 4Myeloid 4Endocrine 4Other solid neoplasm 3Head & Neck 3Thoracic 1Other 1Dermatologic 1

Conditions

Melanoma 284Lymphoma, T-Cell, Cutaneous 108Mycosis Fungoides 83Sezary Syndrome 80Lymphoma, Non-Hodgkin 74Leukemia, Lymphocytic, Chronic, B-Cell 74Lymphoma, Large B-Cell, Diffuse 72Lymphoma, Follicular 71Precursor Cell Lymphoblastic Leukemia-Lymphoma 70Burkitt Lymphoma 68Lymphoma, Mantle-Cell 67Lymphoma, B-Cell, Marginal Zone 67Hodgkin Disease 67Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 65Lymphoma, Large-Cell, Immunoblastic 65Lymphoma, Large-Cell, Anaplastic 62Lymphoma 58Immunoblastic Lymphadenopathy 56Intraocular Lymphoma 43Breast Neoplasms 41Skin Neoplasms 40Neoplasms 37Carcinoma, Renal Cell 35Waldenstrom Macroglobulinemia 33Neoplasm Metastasis 33Uveal Melanoma 29Leukemia, Myeloid, Acute 23Leukemia, Hairy Cell 23Carcinoma, Non-Small-Cell Lung 22Sarcoma 21

Interventions

Oxaliplatin 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Familial ependymoma × Dermatologic × Clear all
NCT00101270 2013-06-05

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
CNSDermatologicGastrointestinalGenitourinaryHead & NeckLymphoidSarcoma

Familial ependymoma, Astrocytoma, Burkitt Lymphoma, Colonic Neoplasms, Medulloblastoma, Melanoma, Nasopharyngeal Neoplasms, Wilms Tumor, Neuroblastoma, Recurrence, Osteosarcoma, Lymphoma, Large B-Cell, Diffuse, Neuroectodermal Tumors, Primitive, Peripheral, Optic Nerve Glioma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡